Selective Chelating Agents for Copper Dysregulation in Neurodegeneration

The patent modifies the chemical structure of chelating agents by introducing specific functional groups (hydroxamic acid groups, thiol groups, amino groups) and adjusting molecular parameters to achieve selective binding to copper ions. This structural parameter change enables effective copper chelation while reducing non-specific interactions that cause toxicity, thereby resolving the contradiction between treatment effectiveness and adverse side effects

The invention designs chelating agents with specific local functional groups positioned to selectively interact with copper ions in the liver. The molecules contain localized binding sites with specific geometries and chemical properties that match copper ion coordination requirements, enabling selective copper removal without affecting other metal ions, thus reducing adverse side effects while maintaining treatment effectiveness

The chelating agents contain localized functional groups (hydroxamic acid, thiol, amino groups) with specific spatial arrangements that create selective binding pockets for copper ions. These local structural features provide geometric and electronic complementarity to copper ion coordination spheres, enabling high selectivity for copper over other metal ions while maintaining strong binding affinity

The invention combines multiple functional groups (hydroxamic acid groups, thiol groups, amino groups, carboxylic acid groups) into composite chelating agent molecules. This composite structure creates multiple interaction sites with different binding characteristics, where the synergistic effect of these groups provides both strong copper binding affinity and high selectivity through multi-point coordination that is specific to copper ion geometry and electronics